{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T07:34:30Z","timestamp":1793000070906,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since the approval of immune checkpoint inhibitors (ICI) and targeted therapies (TT), the number of long-term survivors of metastatic melanoma (LTS) has increased. However, data on their complaints and needs remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the prevalence and spectrum of treatment-related adverse events (TRAEs), psycho-oncological distress and socioeconomic outcomes in LTS, to evaluate association with elevated distress levels and to determine whether these findings support implementation of dedicated survivorship programmes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 15 April 2024, and 9 May 2025 an online survey was conducted among LTS (overall survival &amp;gt; 5\u2005years after stage IV diagnosis) to assess potential TRAEs, financial burden and psychosocial distress. Validated tools and disease-specific questions were used. All skin cancer centres within the German Dermatologic Cooperative Oncology Group and patient support groups were invited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 296 LTS from 40 centres in Austria, Germany and Switzerland participated. Of those, 29.1% (n = 86) had brain metastases, 79.1% (n = 234) had received ICI at any time point and 26.7% (n = 79) had received TT. Distress levels above the threshold were reported by 39.2% of all patients (n = 116\/296) and persistent TRAEs were also reported by 39.2% of the patients who had received at least one systemic therapy (n = 107\/273). Among patients with prior radiotherapy, 29.1% (n = 43\/148) reported persistent TRAEs for either treatment; similarly, 31.4% of patients (n = 93\/296) reported persistent TRAEs after surgery. Cognitive deficits after cerebral radiotherapy and lymph oedema after surgery were the most frequently reported complaints. Persistent TRAEs due to systemic antitumour therapy were significantly associated with elevated distress values (OR 1.99, P = 0.03). Financial constraints were reported by 23.3% (n = 69\/296) of patients. At the time of the survey, 62.3% (n = 96\/154) of patients aged \u2264 65\u2005years were still working, half with reduced hours, and 44.3% (n = 89\/201) of retirees had retired early because of melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A substantial proportion of LTS face persistent physical, psychosocial and financial challenges. To address these unmet needs, implementation of survivorship programmes with validated screening and integrated vocational, financial and psychological counselling is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag374","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:22:38Z","timestamp":1788780158000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond the surface of long-term survival in stage IV melanoma: a multicentre cross-sectional study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-1043","authenticated-orcid":false,"given":"Markus","family":"Reitmajer","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Sch\u00e4ffeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"B\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Rompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Dugas-Breit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus\u00a0V","family":"Heppt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke K","family":"Peitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Jessica","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026102603014502600_ljag374-B1","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026102603014502600_ljag374-B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102603014502600_ljag374-B3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"key":"2026102603014502600_ljag374-B4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00432-023-05533-0","article-title":"Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017","volume":"150","author":"Reitmajer","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026102603014502600_ljag374-B5","doi-asserted-by":"crossref","first-page":"e2426641","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-term survival in patients with advanced melanoma","volume":"7","author":"van Not","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026102603014502600_ljag374-B6","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/cncr.23448","article-title":"Physical and psychological long-term and late effects of cancer","volume":"112","author":"Stein","year":"2008","journal-title":"Cancer"},{"key":"2026102603014502600_ljag374-B7","doi-asserted-by":"crossref","first-page":"105293","DOI":"10.1016\/j.esmoop.2025.105293","article-title":"Financial toxicity and socioeconomic impact of cancer in Europe","volume":"10","author":"Vancoppenolle","year":"2025","journal-title":"ESMO Open"},{"key":"2026102603014502600_ljag374-B8","first-page":"832","article-title":"Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma \u2013 a cross-sectional questionnaire study","volume":"23","author":"Reitmajer","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026102603014502600_ljag374-B9","volume-title":"Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbed\u00fcrftiger Krebspatienten","author":"Herschbach","year":"2010"},{"key":"2026102603014502600_ljag374-B10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-3-642-59410-6_40","article-title":"How to identify patients in need of psychological intervention","volume":"160","author":"Strittmatter","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"2026102603014502600_ljag374-B11","volume-title":"Entwicklung und klinischer Einsatz von Screening-Instrumenten zur Identifikation betreuungsbed\u00fcrftiger Tumorpatienten","author":"Strittmatter","year":"2000"},{"key":"2026102603014502600_ljag374-B12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.6004\/jnccn.2019.0048","article-title":"Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Riba","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2026102603014502600_ljag374-B13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.6004\/jnccn.2022.0004","article-title":"NCCN Distress Thermometer Problem List Update","volume":"20","author":"Donovan","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026102603014502600_ljag374-B14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","article-title":"The Patient Health Questionnaire-2: validity of a two-item depression screener","volume":"41","author":"Kroenke","year":"2003","journal-title":"Med Care"},{"key":"2026102603014502600_ljag374-B15","first-page":"613","article-title":"An ultra-brief screening scale for anxiety and depression: the PHQ-4","volume":"50","author":"Kroenke","year":"2009","journal-title":"Psychosomatics"},{"key":"2026102603014502600_ljag374-B16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpsychores.2004.09.006","article-title":"Detecting and monitoring depression with a two-item questionnaire (PHQ-2)","volume":"58","author":"L\u00f6we","year":"2005","journal-title":"J Psychosom Res"},{"key":"2026102603014502600_ljag374-B17","first-page":"CD015455","article-title":"Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults","volume":"3","author":"Akt\u00fcrk","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102603014502600_ljag374-B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection","volume":"146","author":"Kroenke","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026102603014502600_ljag374-B19","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/annonc\/mdh318","article-title":"Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach","volume":"15","author":"Keller","year":"2004","journal-title":"Ann Oncol"},{"key":"2026102603014502600_ljag374-B20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1054\/bjoc.2001.1724","article-title":"Psychiatric morbidity and its recognition by doctors in patients with cancer","volume":"84","author":"Fallowfield","year":"2001","journal-title":"Br J Cancer"},{"key":"2026102603014502600_ljag374-B21","first-page":"2693","article-title":"A qualitative study investigating Australian cancer service outpatients\u2019 experience of distress screening and management: what is the personal relevance, acceptability and improvement opportunities from patient perspectives?","volume":"30","author":"McCarter","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026102603014502600_ljag374-B22","doi-asserted-by":"crossref","first-page":"e2327145","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026102603014502600_ljag374-B23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026102603014502600_ljag374-B24","doi-asserted-by":"crossref","first-page":"e004509","DOI":"10.1136\/jitc-2022-004509","article-title":"Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026102603014502600_ljag374-B25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ddg.15560","article-title":"Employment, work ability and sick leave in melanoma patients within the first year of diagnosis","volume":"23","author":"Dugas-Breit","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026102603014502600_ljag374-B26","author":"Bund-L\u00e4nder Demografie Portale"},{"key":"2026102603014502600_ljag374-B27","author":"EURES"},{"key":"2026102603014502600_ljag374-B28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pon.2059","article-title":"Melanoma survivors: health behaviors, surveillance, psychosocial factors, and family concerns","volume":"22","author":"Oliveria","year":"2013","journal-title":"Psychooncology"},{"key":"2026102603014502600_ljag374-B29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2023.6158","article-title":"Lived experiences and fear of cancer recurrence among survivors of localized cutaneous melanoma","volume":"160","author":"Mahama","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026102603014502600_ljag374-B30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag374\/71228660\/ljag374.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag374\/71228660\/ljag374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T07:01:57Z","timestamp":1792998117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag374\/8817570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag374","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"article-number":"ljag374"}}